Download MendeleyDesign and Synthesis of Novel Macrocyclic Mer Tyrosine Kinase Inhibitors.
Wang, X., Liu, J., Zhang, W., Stashko, M.A., Nichols, J., Miley, M.J., Norris-Drouin, J., Chen, Z., Machius, M., DeRyckere, D., Wood, E., Graham, D.K., Earp, H.S., Kireev, D., Frye, S.V.(2016) ACS Med Chem Lett 7: 1044-1049
- PubMed: 27994735
- DOI: https://doi.org/10.1021/acsmedchemlett.6b00221
- Primary Citation of Related Structures:
5K0K - PubMed Abstract:
Mer tyrosine kinase (MerTK) is aberrantly elevated in various tumor cells and has a normal anti-inflammatory role in the innate immune system. Inhibition of MerTK may provide dual effects against these MerTK-expressing tumors through reducing cancer cell survival and redirecting the innate immune response. Recently, we have designed novel and potent macrocyclic pyrrolopyrimidines as MerTK inhibitors using a structure-based approach. The most active macrocycles had an EC 50 below 40 nM in a cell-based MerTK phosphor-protein ELISA assay. The X-ray structure of macrocyclic analogue 3 complexed with MerTK was also resolved and demonstrated macrocycles binding in the ATP binding pocket of the MerTK protein as anticipated. In addition, the lead compound 16 (UNC3133) had a 1.6 h half-life and 16% oral bioavailability in a mouse PK study.
Organizational Affiliation:
Center for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina 27599, United States.
